BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $84 at Oppenheimer
October 28, 2021 6:20 AM EDTOppenheimer analyst Leland Gershell raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $84.00 (from $81.00) while maintaining a Perform rating.
The analyst commented, "Much of 3Q21's revenue lightness ($408.7M vs. our/cons $413.8/435.3M) was attributed to order/shipment timing (Aldurazyme,... More
BioMarin Pharma (BMRN) Tops Q3 EPS by 4c
October 27, 2021 4:10 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $408.7 million versus the consensus estimate of $435.89 million.
GUIDANCE:
BioMarin Pharma sees Q4 2021 revenue of $1.82-1.88 billion, versus the consensus of... More
